BeiGene (HKG:6160, SHA:688235) recorded a net income of $1.3 million in the first quarter, compared with a net loss of $251.2 million in the year-ago period, a Wednesday Hong Kong bourse filing said.
The company did not make any earnings per share in the three months, while it had incurred a loss per share of $0.19 in the corresponding period of the last year.
Revenue for the pharmaceutical company rose 49% to $1.12 billion in the quarter from $751.7 million a year prior, driven primarily by higher product sales under the BRUKINSA brand in the US and Europe.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.